NKA Bio | Baltimore Trauma Resuscitation Startup
Description: NKA Bio was founded with a mission to improve trauma care by solving shock. The company is focused on its primary product NKA01 for Trauma Resuscitation. The early-stage pipeline in development includes programs for septic shock, acute lung injury, and heart attack resuscitation.
NKA Bio is developing new medicines to improve critical care. Our lead product is NKA01, a temperature-stable antibody for trauma patients.
When you are severely injured, it is a race against time to get to surgery. The average person dies 8 minutes before lifesaving treatment can be delivered.
But in the future, when minutes count, our antibody will buy hours . At NKA Bio, our treatment presses pause on death. With an injection of NKA01 by EMS, our drug could buy more time for transport and lifesaving surgery.
NKA Bio | Baltimore Trauma Resuscitation Startup